Release Date: November 23, 2015
Expiration Date: November 23, 2016
Media: Print with online posttest, evaluation, and request for credit

Overview

This activity is designed to inform physicians about the latest treatment advances and data in the management of triple-negative breast cancer (TNBC), including approved and investigational treatment strategies.

Instructions For This Activity & Receiving Credit You will need to login to participate in the activity. Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation. At the end of the activity, "educational content/video" will be available for your reference. In order to receive a CME certificate, participants must complete the activity. Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit.  Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This activity is directed toward medical oncologists, nurses, and nurse practitioners who manage and treat patients with TNBC. Breast surgeons, surgical oncologists, radiation oncologists, pathologists, fellows, physician assistants, and other healthcare providers interested in the treatment of TNBC are also invited to participate.

Learning Objectives

After participating in this CME activity, learners should be better prepared to:

• Discuss how biomarkers are being used to select treatment regimens that may be particularly effective in certain subgroups of patients with advanced TNBC
• Summarize phase I clinical trial outcomes reported with immunotherapy agents that are under investigation in advanced TNBC
• Describe recent research efforts that have sought to optimize neoadjuvant treatment of patients with early-stage TNBC

Medical Writer

Kelly McCoy Hayden, PhD
Disclosure: No relevant financial relationships with commercial interests to disclose.

The American Journal of Hematology/ Oncology^® Editorial Board

Debu Tripathy, MD
Professor and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosure: Grant/research support from Genentech/Roche, Pfizer, Puma Inc, and Novartis (clinical trial support contracted to the University of Southern California and MD Anderson Cancer Center); consultant for Eisai, Oncoplex Diagnostics, Merck, and Novartis.

Faculty

Tiffany A. Traina, MD
Assistant Attending Physician
Breast Medicine Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
Assistant Professor of Medicine
Weill Cornell Medical College
New York, NY
Disclosure: Consultant: Genentech/Roche, Eisai, Halozyme, Mundipharma, Medivation, Pfizer, AstraZeneca, Bayer, and Immunomedics; grant/research support: Medivation, Eisai, Pfizer, Novartis, and Myriad Genetics.

Staff/Planner Disclosures and Conflict of Interest Resolution

The staff of Physicians' Education Resource^®, LLC, (PER^®) and the editorial staff of The American Journal of Hematology/Oncology^® have no relevant financial relationships with commercial interests to disclose.

In accordance with Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support^SM, PER^® resolved all conflicts of interest prior to the release of this CME activity using a multistep process.

Accreditation/Credit Designation

Physicians' Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource^®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is funded by Physicians' Education Resource^®, LLC.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for CME purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.

Disclaimer

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^®.

Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

• A Pentium-based PC or compatible computer
• At least 64MB of RAM
• Windows 95/98/NT/ME/2000/XP/Vista system software
• Screen resolution of 1024 x 786 or larger recommended
• PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

• A PowerPC processor-based Macintosh computer
• At least 64MB of RAM
• Mac OS 7.5 or later
• Screen resolution of 1024 x 786 or larger recommended
• PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise